Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct;12(10):303-312.
doi: 10.5489/cuaj.5616.

Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH): 2018 update

J Curtis Nickel  1 , Lorne Aaron  2 , Jack Barkin  3 , Dean Elterman  4 , Mahmoud Nachabé  2 , Kevin C Zorn  5
Affiliations

Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH): 2018 update

J Curtis Nickel et al. Can Urol Assoc J. 2018 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: Dr. Nickel has been a consultant for Astellas, Auxillium, Eli Lilly, Farr Labs, Ferring, GSK, Pfizer, Redleaf Pharma, Taris Biomedical, Tribute, and Trillium Therapeutics; a lecturer for Astellas and Eli Lilly; and has participated in clinical trials supported by Eli Lilly, GSK, J&J, Pfizer, and Taris Biomedical. Dr. Aaron has attended advisory boards for AbbVie and Janssen; has been a speaker for Ferring and Janssen; holds investments in Johnson & Johnson; and has participated in clinical trials supported by Asetllas, Ferring, and Janssen. Dr. Elterman has attended advisory boards for, is a speaker for, and has received grant funding from Allergan, Astellas, Boston Scientific, Ferring, Medtronic, and Pfizer; and has participated in clinical trials supported by Astellas and Medtronic. Dr. Zorn has received honoraria from Boston Scientific and as a proctor/lecturer for Greenlight; and participated in the WATER2 clinical trial with aquablation supported by Procept Biorobotics. The remaining authors report no competing personal or financial interests.

Figures

Fig. 1
Fig. 1
Algorithm of appropriate diagnostic steps in the workup of a typical patient with male lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH). PE: physical exam; PSA: prostate-specific antigen; PVR: post-void residual; U/A: urinalysis.
Fig. 2
Fig. 2
Male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH) management algorithm. ED: erectile dysfunction; PDE5: phosphodiesterase type 5; PSA: prostate-specific antigen.
Fig. 3
Fig. 3
Treatment algorithm of bothersome lower urinary tract symptoms (LUTS) refractory to conservative/medical treatment or in cases of absolute operation indications. The flowchart was stratified by the patient’s ability to have anesthesia, cardiovascular risk, and prostate volume. *Current standard/first choice. The alternative treatments are presented in alphabetical order. **Must exclude the presence of a middle lobe. BPH: benign prostatic hyperplasia; B-TURP: bipolar transurethral resection of the prostate; HoLEP: holmium laser enucleation of the prostate; M/TURP: monopolar transurethral resection of the prostate; PVP: photoselective vaporization of the prostate; TUIP: transurethral incision of the prostate; TUMT: transurethral microwave therapy.
See this image and copyright information in PMC

References

    1. Nickel JC, Mendez-Probst CE, Whelan TF, et al. 2010 update: Guidelines for the management of benign prostatic hyperplasia. Can Urol Assoc J. 2010;4:308–14. doi: 10.5489/cuaj.10124. - DOI - PMC - PubMed
    1. McVary KT, Roehrborn CG, Avins AL, et al. American Urological Association guideline: Management of benign prostatic hyperplasia (BPH) [Accessed Aug. 28, 2018]. Published 2010; reviewed and validity confirmed 2014. Available at http://www.auanet.org/guidelines/benign-prostatic-hyperplasia-(2010-revi...
    1. Gratzke C, Bachmann A, Descazeaud A, et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2015;67:1099–1109. doi: 10.1016/j.eururo.2014.12.038. - DOI - PubMed
    1. GRADE Guidelines 15. [Accessed Aug. 28, 2018]. Available at http://www.gradeworkinggroup.org/
    1. Abrams P, Cardozo L, Wagg A, et al. Incontinence. 6th International Consultation on Incontinence; Tokyo. September 2016; ICUD; 2017.